All rights reserved. No reuse allowed without permission.

20 Hye Won Jeong, M.D., Ph.D., e-mail: hwjeong@chungbuk.ac.kr

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

21 **Abstract**

22 Memory T cells contribute to rapid viral clearance during re-infection, but the longevity and 23 differentiation of SARS-CoV-2-specific memory T cells remain unclear. We conducted direct 24 ex vivo assays to evaluate SARS-CoV-2-specific CD4⁺ and CD8⁺ T cell responses in COVID-19 25 convalescents up to 254 days post-symptom onset (DPSO). Here, we report that memory T 26 cell responses were maintained during the study period. In particular, we observed 27 sustained polyfunctionality and proliferation capacity of SARS-CoV-2-specific T cells. Among 28 SARS-CoV-2-specific CD4⁺ and CD8⁺ T cells detected by activation-induced markers, the 29 proportion of stem cell-like memory T (T_{SCM}) cells increased, peaking at approximately 120 30 DPSO. Development of T_{SCM} cells was confirmed by SARS-CoV-2-specific MHC-I multimer 31 staining. Considering the self-renewal capacity and multipotency of T_{SCM} cells, our data 32 suggest that SARS-CoV-2-specific T cells are long-lasting after recovery from COVID-19. The 33 current study provides insight for establishing an effective vaccination program and 34 epidemiological measurement.

35 **Introduction**

 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes coronavirus disease 2019 (COVID-19), an ongoing pandemic disease that threatens public 38 health¹. As of January 17, 2021, more than 93.2 million confirmed cases had been reported, 39 and over 2 million deaths worldwide². After SARS-CoV-2 infection, some patients, particularly elderly patients, develop severe COVID-19 that is associated with hyper- inflammatory responses^{3,4}. Global efforts are underway to prevent the transmission of SARS- CoV-2 and to develop novel vaccines and therapeutic strategies. A thorough understanding of the immune responses against SARS-CoV-2 is urgently needed to control the COVID-19 pandemic.

45 Increasing evidence has demonstrated that SARS-CoV-2-specific memory T cell 46 responses are elicited after recovery from COVID-19. A number of studies have reported 47 SARS-CoV-2-specific memory T cell responses in the early convalescent phase of COVID-19⁵⁻⁹. 48 SARS-CoV-2-specific CD4⁺ and CD8⁺ T cells have been detected in 100% and ~70% of 49 convalescent individuals a short time after resolution⁵. Recently, memory T cells were shown 50 to contribute to protection against SARS-CoV-2 re-challenge in a rhesus macaque model¹⁰. 51 Considering that T cell responses to SARS-CoV-1 and Middle East respiratory syndrome 52 coronavirus (MERS-CoV) are long-lasting, up to >17 years^{6,11-13}, SARS-CoV-2-specific memory 53 T cells are expected to be maintained long-term and to contribute to rapid viral clearance 54 during re-infection. A very recent study has examined SARS-CoV-2-specific T cell responses 55 up to 8 months after infection using activation-induced marker (AIM) assays¹⁴.

56 Following natural infection or vaccination, the generation of effective and persistent 57 T cell memory is essential for long-term protective immunity to the virus. Among diverse 58 memory T cell subsets, stem cell-like memory T (T_{SCM}) cells were recently reported to have 59 the capacity for self-renewal and multipotency to repopulate the broad spectrum of 60 memory and effector T cell subsets^{15,16}. Thus, the successful generation of T_{SCM} cells is 61 required for long-term protective T cell immunity¹⁶. For example, long-lived memory T cells 62 following vaccination with live-attenuated yellow fever virus (YFV) exhibit stem cell-like 63 properties and mediate lifelong protection^{17,18}. However, limited knowledge is available on 64 the differentiation of SARS-CoV-2-specific memory T cells following recovery from COVID-19, 65 particularly the generation of T_{SCM} cells.

 In the present study, we performed a comprehensive analysis of SARS-CoV-2-specific 67 CD4⁺ and CD8⁺ T cell responses in peripheral blood mononuclear cells (PBMCs) from individuals with SARS-CoV-2 infection over 8 months post-infection. Using diverse T cell assays, we found that SARS-CoV-2-specific memory T cell responses were maintained 8 months after the infection. In addition, we analyzed the differentiation of SARS-CoV-2- specific memory T cells during the study period and revealed the successful generation of T_{SCM} cells. We also assessed the effector functions and proliferation capacity of long-term 73 memory CD4⁺ and CD8⁺ T cells.

74 **Results**

75 *Study cohort*

 We recruited 94 individuals with SARS-CoV-2 infection. The peak disease severity was evaluated according to the NIH severity of illness categories¹⁹: asymptomatic (n=6), mild (n=44), moderate (n=23), severe (n=13), and critical (n=8). Whole blood samples were obtained longitudinally (2-4 time points) from 38 patients or at a single time point from 56 80 patients. Whole blood was collected 1 to 254 days post-symptom onset (DPSO). Finally, a total of 160 PBMC samples were analyzed. Among 160 PBMC samples, 33 samples were obtained in the acute phase when viral RNA was still detected (1 - 33 DPSO), and 127 83 samples were obtained in the convalescent phase after the negative conversion of viral RNA (31 - 254 DPSO). In the current study, we defined the acute phase as 1 - 30 DPSO, and the convalescent phase as 31 - 254 DPSO. The demographic and clinical characteristics of enrolled patients are presented in Supplementary Table 1.

87

88 *SARS-CoV-2-specific T cell responses are sustained 8 months after the infection*

89 First, we performed direct *ex vivo* interferon-γ (IFN-γ) enzyme-linked immunospot 90 (ELISpot) assays following stimulation of PBMCs with overlapping peptide (OLP) pools 91 spanning the spike (S), membrane (M), and nucleocapsid (N) proteins of SARS-CoV-2. S-, M-, 92 and N-specific IFN- γ spot numbers increased during the acute phase. Subsequently, there 93 was a decreasing tendency until 60 - 120 DPSO, and the IFN- γ responses were maintained 94 over 8 months (Fig. 1a). These kinetics were also observed when S-, M-, and N-specific IFN- γ 95 spot numbers were summed (Fig. 1a). In each PBMC sample, all three OLP pools evenly 96 contributed to the IFN- γ responses without antigen dominance (Fig. 1b). We divided 97 convalescent samples into three groups based on the DPSO at sample collection: T1 (31 - 99 98 DPSO), T2 (100 - 199 DPSO), and T3 (200 - 254 DPSO). We found no significant difference in 99 IFN- γ spot numbers among groups (Fig. 1c), and an even contribution of antigens for the IFN-100 γ response was maintained among groups (Extended Data Fig. 1). Next, we focused on 101 longitudinally tracked samples from 30 individuals in the convalescent phase. S-, M-, and N-102 specific and summed IFN- γ spot numbers were stable during the convalescent phase (Fig. 103 1d). When we compared paired samples from the same patient at two time points (t1, 31 -104 100 DPSO; t2, 200 - 254 DPSO), we found no significant difference in IFN-γ spot numbers

105 (Fig. 1e).

106 We also evaluated SARS-CoV-2-specific T cell responses by AIM assays^{5,20,21} following 107 stimulation of PBMCs with OLP pools of S, M, and N. CD137+OX40+ cells were considered 108 SARS-CoV-2-specific cells among CD4⁺ T cells, and CD137⁺CD69⁺ cells were considered SARS- 109 CoV-2-specific cells among CD8⁺ T cells⁵ (Fig. 2a, b). We confirmed a strong positive 110 correlation between the frequency of CD137+OX40+ cells and the frequencies of alternative 111 AIM⁺ cells (OX40⁺CD154⁺ or CD137⁺CD154⁺ cells) among CD4⁺ T cells (Extended Data Fig. 2). 112 The frequency of S-, M-, and N-specific CD137⁺OX40⁺ cells among CD4⁺ T cells increased 113 during the acute phase, decreased until 60 DPSO, and then was maintained over 8 months 114 (Fig. 2c). When the frequency of S-, M-, and N-specific CD137⁺OX40⁺ cells was summed, 115 similar kinetics were observed (Fig. 2c). The frequency of CD137⁺CD69⁺ cells among CD8⁺ T 116 cells was relatively low compared to the frequency of CD137+OX40+ cells among CD4+ T cells, 117 but exhibited similar kinetics (Fig. 2c). We also observed a positive correlation between the 118 frequency of CD137⁺OX40⁺ cells among CD4⁺ T cells and the frequency of CD137⁺CD69⁺ cells 119 among CD8⁺ T cells (Extended Data Fig. 3).

120 Collectively, these results indicate that SARS-CoV-2-specific T cell responses are long-121 lasting over 8 months in COVID-19 convalescents.

122

123 *SARS-CoV-2-specific TSCM cells develop after the infection*

124 Next, we examined the differentiation status of SARS-CoV-2-specific AIM⁺ T cells 125 based on CCR7 and CD45RA expression in CD4⁺ (Fig. 3a) and CD8⁺ (Fig. 3b) T cell populations. 126 Among SARS-CoV-2-specific AIM⁺CD4⁺ T cells, the proportion of CCR7⁺CD45RA⁻ (T_{CM}) cells 127 was maintained at approximately 50% on average during the study period, and the 128 proportion of CCR7⁻CD45RA⁻ (T_{EM}) cells increased up to approximately 35% on average until 129 60 DPSO and then maintained thereafter (Fig. 3c). CCR7 CD45RA⁺ (T_{EMRA}) cells were a minor 130 population (< 5%; Fig. 3c). Notably, the proportion of CCR7⁺CD45RA⁺ cells, which include 131 both naïve and T_{SCM} cells, was approximately 30% on average in the acute phase, decreasing 132 to approximately 10% on average by 60 DPSO and then maintained thereafter (Fig. 3c). 133 Among SARS-CoV-2-specific AIM⁺CD8⁺ T cells, the proportion of CCR7⁺CD45RA⁻ (T_{CM}) 134 cells was approximately 20% on average in the acute phase and gradually decreased during

135 the study period (Fig. 3d). The proportion of CCR7 CD45RA (T_{FM}) cells increased up to 50%

136 on average until 60 DPSO and was maintained thereafter (Fig. 3d). The proportion of CCR7-137 CD45RA⁺ (T_{EMRA}) cells and CCR7⁺CD45RA⁺ cells was maintained (~25% and 25-35% on 138 average, respectively) during the study period (Fig. 3d).

139 We further investigated whether CCR7⁺CD45RA⁺ cells include T_{SCM} cells, which have 140 a self-renewal capacity and multipotency for differentiation into diverse T cell subsets, by 141 examining CD95, a marker of T_{SCM} cells^{15,16}. In both AIM⁺CD4⁺ and AIM⁺CD8⁺ T cells, CD95⁺ 142 cells were a dominant population among CCR7⁺CD45RA⁺ cells (Fig. 3e), indicating that the 143 CCR7⁺CD45RA⁺ cells among AIM⁺CD4⁺ or AIM⁺CD8⁺ T cells are mainly T_{SCM} cells. The 144 frequency of T_{SCM} cells among both AIM⁺CD4⁺ and AIM⁺CD8⁺ T cells gradually increased until 145 120 DPSO, when it reached a stable plateau (Fig. 3e). We found no significant difference in 146 the frequency of T_{SCM} cells among AIM⁺CD4⁺ and AIM⁺CD8⁺ T cells between T1 (31 - 99 147 DPSO), T2 (100 - 199 DPSO), and T3 (200 - 254 DPSO; Extended Data Fig. 4a, b).

148

149 *Successful development of SARS-CoV-2-specific TSCM cells is confirmed by direct ex vivo* 150 *MHC-I multimer staining*

151 To validate the results from *in vitro* stimulation-based AIM assays, we detected 152 SARS-CoV-2-specific CD8⁺ T cells by performing direct *ex vivo* MHC-I multimer staining and 153 examined the differentiation status of MHC-I multimer⁺ cells. We used an HLA-A*02 154 multimer loaded with SARS-CoV-2 S²⁶⁹ (YLQPRTFLL) peptide that has a low degree of 155 homology to the human common cold coronaviruses (ccCoVs)^{22,23}. MHC-I multimer⁺ cells 156 were detected during the study period until 234 DPSO (Fig. 4a, b), and we determined the 157 proportions of T_{CM} (CCR7⁺CD45RA⁻), T_{EM} (CCR7⁻CD45RA⁻), T_{EMRA} (CCR7⁻CD45RA⁺), and T_{SCM} 158 (CCR7+CD45RA+CD95+) cells among MHC-I multimer+ cells (Fig. 4c). Influenza A virus (IAV)-159 and cytomegalovirus (CMV)-specific MHC-I multimers were also used to stain PBMCs from 160 healthy donors. Similar to the data from AIM⁺CD8⁺ T cells, T_{EM} and T_{EMRA} cells were the 161 dominant populations among SARS-CoV-2-specific MHC-I multimer⁺ cells, whereas T_{CM} cells 162 were a minor population during the study period (Fig. 4d). Among IAV- and CMV-specific 163 MHC-I multimer⁺ cells from healthy donors, T_{EM} and T_{EMRA} cells were dominantly present, 164 whereas T_{CM} cells were scarcely detected. T_{SCM} cells were also detected among SARS-CoV-2-165 specific MHC-I multimer⁺ cells during the study period, but not among IAV- and CMV-specific 166 cells (Fig. 4d). In particular, the frequency of T_{SCM} cells among SARS-CoV-2-specific MHC-I

167 multimer⁺ cells was high 60 – 125 DPSO.

168 A recent study has revealed two distinct subsets of CCR7⁺ stem cell-like progenitors: 169 CCR7⁺PD-1⁻TIGIT⁻ cells with stem cell-like features and CCR7⁺PD-1⁺TIGIT⁺ cells with exhausted 170 traits²⁴. Therefore, we examined the expression of PD-1 and TIGIT in SARS-CoV-2-specific 171 MHC-I multimer⁺ T_{SCM} cells. The frequency of PD-1⁺TIGIT⁺ cells was significantly lower among 172 SARS-CoV-2-specific T_{SCM} cells than among total CD8⁺ T cells (Fig. 4e), confirming that SARS-173 CoV-2-specific T_{SCM} cells are *bona fide* stem-like memory cells.

174

175 *Polyfunctionality and proliferation capacity are preserved in long-term SARS-CoV-2-*

176 *specific T cells*

177 As we observed the generation of SARS-CoV-2-specific T_{SCM} cells with self-renewal 178 capacity and multipotency, we aimed to examine the kinetics of the polyfunctionality of 179 SARS-CoV-2-specific T cells during the study period. To this end, we performed intracellular 180 cytokine staining of IFN-γ, IL-2, TNF, and CD107a following stimulation with OLP pools of S, 181 M, and N and analyzed the polyfunctionality of CD4⁺ and CD8⁺ T cells (Fig. 5a). We defined 182 polyfunctional cells as cells exhibiting positivity for \geq 2 effector functions. Among SARS-CoV-183 2-specific CD4⁺ and CD8⁺ T cells, the average proportion of polyfunctional cells was 25 - 40% 184 and 30 - 50%, respectively, 60 DPSO, and was maintained until 254 DPSO (Fig. 5b). We found 185 no significant difference in the frequency of polyfunctional cells among SARS-CoV-2-specific 186 CD4⁺ and CD8⁺ T cells between T1 (31 - 99 DPSO), T2 (100 - 199 DPSO), and T3 (200 - 254 187 DPSO; Fig. 5c). Preserved polyfunctionality among SARS-CoV-2-specific CD4⁺ and CD8⁺ T cells 188 was also observed when polyfunctionality was evaluated according to the number of 189 positive effector functions (Fig. 5d).

 Finally, we examined the antigen-induced proliferation capacity of long-term SARS- CoV-2-specific memory T cells. We performed CellTrace Violet (CTV) dilution assays and Ki-192 67 staining using PBMCs obtained after 200 DPSO. CD4⁺ T cells exhibited a robust proliferative response following *in vitro* stimulation with the S OLP pool (Fig. 5e), indicating that SARS-CoV-2-specific memory T cells elicit rapid recall responses upon viral re-exposure. Considering preserved polyfunctionality and proliferation capacity of SARS-CoV-2- 196 specific memory T cells, the current data indicate that memory T cells contribute to protective immunity against re-infection even 8 months after the primary infection.

198 **Discussion**

 Memory T cells play a crucial role in viral clearance during re-infection, but the longevity and differentiation status of SARS-CoV-2-specific memory T cells among COVID-19 convalescents remain unclear. In the present study, we demonstrated that SARS-CoV-2- specific memory T cell responses were maintained in COVID-19 convalescents 8 months 203 post-infection. Notably, we found that SARS-CoV-2-specific T_{SCM} cells were successfully developed, indicating that SARS-CoV-2-specific T cell memory may be long-lasting in COVID-205 19 convalescents. These findings were supported by the SARS-CoV-2-specific T cells from PBMCs obtained after 200 DPSO exhibiting sustained polyfunctionality and proliferation capacity. Our results may fill a gap in understanding T cell memory responses after recovery from SARS-CoV-2 infection.

209 Recent studies suggest critical roles of T cells in the clearance of SARS-CoV-2 and 210 protection from developing severe COVID-19. In particular, it has been shown that 211 coordination of adaptive immune responses, including CD4+ T cell, CD8+ T cell, and antibody 212 responses, is essential for controlling COVID-19²⁰. Notably, peak disease severity has been 213 shown to inversely correlate with the frequency of SARS-CoV-2-specific CD4⁺ and CD8⁺ T cells 214 instead of SARS-CoV-2 antibody titers²⁰. In another study, T cell responses were detected 215 among COVID-19 convalescents without detectable SARS-CoV-2 $\lg G^{25}$. In a rhesus macaque 216 model, CD8-depleted convalescent animals exhibited limited viral clearance in the 217 respiratory tract upon SARS-CoV-2 re-challenge, suggesting that $CD8⁺$ T cells contribute to 218 viral clearance during SARS-CoV-2 re-infection¹⁰. Collectively, these studies strongly 219 demonstrate a protective role of T cells in COVID-19.

220 Currently, we do not have exact information on how long adaptive immune memory 221 lasts in COVID-19 convalescents. Whether antibody responses to SARS-CoV-2 wane over 222 time in patients who have recovered from COVID-19 remains controversial²⁶⁻²⁸. Previous 223 studies on SARS-CoV-1 and MERS-CoV infection have shown that T cell responses were more 224 enduring compared to antibody responses $12,13$. A recent study detected SARS-CoV-1-specific 225 $\,$ T cell responses 17 years after infection⁶. Similarly, slow decay of SARS-CoV-2-specific 226 memory T cells is expected. In the present study, we demonstrated the maintenance of 227 SARS-CoV-2-specific memory T cell responses in COVID-19 convalescents over 8 months 228 post-infection using a battery of T cell assays. Given that vaccination programs for

229 prophylaxis of SARS-CoV-2 infection are being launched worldwide, another question is how 230 long memory T cells elicited by vaccination will last. Vaccine-induced memory T cells may 231 differ in phenotype and durability from infection-induced memory T cells, which should be 232 addressed in future studies.

 A series of studies have reported the existence of SARS-CoV-2-reactive T cell responses among unexposed individuals, suggesting that memory T cells induced by 235 previous ccCoV infection are cross-reactive to SARS-CoV-2 proteins^{5,29-32}. Therefore, in the present study, we could not distinguish *de novo* primed T cells by SARS-CoV-2 infection from pre-existing, cross-reactive ccCoV-specific T cells. However, we could selectively examine *de novo* primed SARS-CoV-2-specific T cells by staining with an HLA-A*02 multimer loaded with SARS-CoV-2 S²⁶⁹ (YLQPRTFLL) peptide. This epitope peptide has a low degree of homology 240 with ccCoVs, including OC43, HKU1, 229E, and NL63^{22,23}. In future studies of SARS-CoV-2- specific T cell responses, cross-reactive epitope peptides and SARS-CoV-2-specific epitope peptides will need to be used separately³⁰.

243 **Among distinct subsets of memory T cells, T_{SCM} cells possess a superior ability for** 244 self-renewal, memory recall responses, and multipotency to reconstitute diverse memory 245 subsets¹⁵. Therefore, long-term T cell memory relies on the successful generation of T_{SCM} 246 cells¹⁶. Previous studies showed that long-lasting YFV-specific CD8⁺ T cells resemble T_{SCM} 247 cells^{17,18}. We and others have also suggested the generation of SARS-CoV-2-specific T_{SCM} cells 248 in the convalescent phase of COVID-19 on the basis of the expression of CCR7 and 249 CD45RA^{8,23}. However, these studies on COVID-19 patients did not examine the definitive 250 marker of T_{SCM} cells, CD95. In the present study, we delineated the kinetics of T_{SCM} cells using 251 both AIM assays and MHC-I multimer staining, and observed the successful generation of 252 T_{SCM} cells in COVID-19 convalescents. In line with these findings, we also found sustained 253 polyfunctionality and proliferation capacity, suggesting efficient memory recall responses. A 254 recent study has proposed that CCR7⁺ stem-like progenitor cells are composed of two 255 separate populations, which are distinguished by PD-1 and TIGIT expression²⁴. We 256 demonstrated that PD-1 and TIGIT are rarely expressed in SARS-CoV-2-specific T_{SCM} cells, 257 indicating that SARS-CoV-2-specific T_{SCM} cells are not exhausted-like progenitors, but *bona* 258 *fide* stem-like memory cells.

259 Polyfunctional T cells, which exert multiple effector functions simultaneously, play a

260 critical role in host protection against viral infection³³⁻³⁵. For example, polyfunctional CD8⁺ T cells are preserved in human immunodeficiency virus-infected long-term non-progressors³⁴. In addition, polyfunctional T cell responses are associated with effective control of hepatitis 263 C virus (HCV)³⁵. It has also been reported that virus-specific polyfunctional T cells can be 264 successfully developed by immunization with vaccinia virus³⁶ and an HCV vaccine³⁷. 265 Collectively, polyfunctional memory T cells control viral infection more efficiently than monofunctional T cells. Therefore, generation of polyfunctional memory T cells following 267 natural infection or vaccination is expected to confer protective immunity. In this regard, the sustained polyfunctionality of long-term SARS-CoV-2-specific T cells observed in our study is highly suggestive of long-lasting protective immunity in COVID-19 convalescents. In summary, we conducted a comprehensive analysis of SARS-CoV-2-specific memory T cell responses over 8 months post-infection. Our current analysis provides valuable information regarding the longevity and differentiation of SARS-CoV-2-specific 273 memory T cells elicited by natural infection. These data add to our basic understanding of memory T cell responses in COVID-19, which aids in establishing an effective vaccination program and epidemiological measurement.

Methods

Patients and specimens

 In this study, 94 patients with PCR-confirmed SARS-CoV-2 infection were enrolled from Ansan Hospital and Chungbuk National University Hospital, Republic of Korea. Peripheral blood was obtained from all patients with SARS-CoV-2 infection. We also obtained 281 peripheral blood from seven healthy donors. In six asymptomatic patients, the date of the first admission was regarded as 7 DPSO because the date of the first admission among symptomatic patients was an average 7 DPSO. This study was reviewed and approved by the institutional review board of all participating institutions and conducted according to the principles of the Declaration of Helsinki. Informed consent was obtained from all donors and patients.

 PBMCs were isolated by density gradient centrifugation using Lymphocyte Separation Medium (Corning). After isolation, the cells were cryopreserved in fetal bovine serum (FBS; Corning) with 10% dimethyl sulfoxide (DMSO; Sigma-Aldrich) until use.

Ex vivo IFN-γ enzyme-linked immunospot assay

 Plates with hydrophobic polyvinylidene difluoride membrane (Millipore, Billerica, MA) were coated with 2 μg/mL anti-human monoclonal IFN-γ coating antibody (clone 1-D1K, Mabtech) overnight at 4°C. The plates were washed with sterile phosphate-buffered saline (PBS) and blocked with 1% bovine serum albumin (Bovogen) for 1 hour at room temperature (RT). 700,000 PBMCs were seeded per well and stimulated with 1 μg/mL OLP pools spanning SARS-CoV-2 spike, membrane, and nucleocapsid proteins (Miltenyi Biotec) for 24 hours at 298 37°C. We used 10 μ g/mL phytohemagglutinin as a positive control and an equimolar amount of DMSO as a negative control. Plates were washed with 0.05% Tween-PBS (Junsei Chemical) and incubated with 0.25 μg/mL biotinylated anti-human monoclonal IFN-γ antibody (clone 7-B6-1, Mabtech) for 2 hours at RT. After washing, streptavidin-alkaline phosphatase (Invitrogen) was added sequentially. Precipitates were detected with AP color reagent (Bio- Rad) and the reaction stopped by rinsing with distilled water. Spot-forming units were quantified using an automated ELISpot reader (AID). To quantify SARS-CoV-2-specific responses, spots in the negative control wells were subtracted from the OLP-stimulated wells.

Multi-color flow cytometry

Proliferation assays

 PBMCs were labeled using the CellTrace™ Violet Cell Proliferation Kit (Invitrogen) at 339 a concentration of 1.0 x 10⁶ cells/mL for 20 minutes at 37°C. We then added 1% FBS-PBS to the cells for 5 minutes at RT to quench unbound dyes. Cells were washed and cultured in RPMI 1640 (Corning) containing 10% FBS (Corning) and 1% penicillin-streptomycin (Welgene) at a concentration of 500,000 cells per well in the presence of 1 μg/mL SARS-CoV- 2 spike peptide pools and 1 μg/mL anti-human CD28 and CD49d mAbs (clone L293 and L25 respectively, BD Biosciences) for 120 hours. Stimulation with an equal concentration of DMSO in PBS was performed as a negative control. After incubation, cells were harvested and stained with antibodies for analysis by flow cytometry.

Data quantification and statistical analysis

 Data were calculated as background-subtracted data. Background-subtracted data were derived by subtracting the value after DMSO stimulation. When three stimuli were combined, the value after each stimulation was combined and we subtracted triple the value derived from DMSO stimulation.

 Statistical analyses were performed using GraphPad Prism version 9 for Windows (GraphPad Software). Significance was set at p<0.05. The Wilcoxon signed-rank test was used to compare data between two paired groups. In addition, the Kruskal-Wallis test with Dunns' multiple comparisons test was used to compare non-parametric data between multiple unpaired groups. To assess the significance of correlation, the Spearman correlation test was used. In cross-sectional analyses, a non-parametric local regression (LOESS) function was employed with 95% confidence interval.

Data availability

- Data relating to the findings of this study are available from the corresponding author upon
- reasonable request.
-

Acknowledgments

- This work was supported by the Samsung Science and Technology Foundation under Project
- Number SSTF-BA1402-51, and the Mobile Clinic Module Project funded by KAIST.
-

Author Contributions

- J.H.J., M.-S.R., H.W.J., W.S.C., and E.-C.S. designed the research. H.K.C., J.H.J., H.S., D.W.P.,
- H.W.J., and W.S.C. collected clinical specimens. J.H.J., M.-S.R., and M.S. performed
- experiments. J.H.J., M.-S.R., S.-H.P., and E.-C.S. analyzed the results. J.H.J., M.-S.R. and E.-
- C.S. wrote the manuscript.
-

Competing Interests

The authors have no competing interests.

References

All rights reserved. No reuse allowed without permission.

450 with early control of hepatitis C virus. *Gastroenterology* **143**, 1048-1060.e4 (2012).

Figure Legends

 Fig. 1. SARS-CoV-2-specific IFN-γ responses over 8 months post-infection. PBMC samples (n=135) from individuals with SARS-CoV-2 infection (n=76) were stimulated with OLPs of S, 454 M, or N (1 μ g/mL) for 24 h and the spot-forming units of IFN- γ -secreting cells examined by ELISpot. **a,** Scatter plots showing the relationship between DPSO and IFN-γ responses. The 456 black line is a LOESS smooth nonparametric function, and the grey shading represents the 95% confidence interval. **b,** The composition of S-, M-, or N-specific IFN-γ responses among the total IFN-γ responses in each individual. **c,** IFN-γ responses were compared between T1 (n=46, 31 - 99 DPSO), T2 (n=37, 100 - 199 DPSO), and T3 (n=23, 200 - 254 DPSO). Data are presented as median and interquartile range (IQR). **d,e,** IFN-γ responses were analyzed in longitudinally tracked samples (n=82) from 30 individuals. **d,** Scatter plots showing the relationship between DPSO and IFN-γ responses. **e,** IFN-γ responses was compared between paired samples at two time points (n=14; t1, 31 - 100 DPSO; t2, 200 - 254 DPSO). Statistical analysis was performed using the Kruskal-Wallis test with Dunns' multiple comparisons test (**c**) or the Wilcoxon signed-rank test (**e**). n.s, not significant.

467 • Fig. 2. Kinetics of SARS-CoV-2-specific activation-induced marker (AIM)⁺ T cells. PBMC samples (n=125) from individuals with SARS-CoV-2 infection (n=69) were stimulated with 169 OLPs of S, M, or N (1 μg/mL) for 24 h. The frequency of AIM⁺ (CD137⁺OX40⁺) cells among 470 CD4⁺ T cells and the frequency of AIM⁺ (CD137⁺CD69⁺) cells among CD8⁺ T cells were analyzed. **a,b,** Representative flow cytometry plots showing the frequency of AIM⁺ cells 472 among CD4⁺ (a) or CD8⁺ (b) T cells. **c**, Scatter plots showing the relationship between DPSO 473 and the frequency of AIM⁺ cells among CD4⁺ (left) or CD8⁺ (right) T cells. The black is a LOESS smooth nonparametric function, and the grey shading represents the 95% confidence interval.

Fig. 3. Differentiation status of SARS-CoV-2-specific AIM⁺ T cells. a-d, PBMC samples (n=124) from individuals with SARS-CoV-2 infection (n=68) were stimulated with OLPs of S,

479 M, or N (1 μg/mL) for 24 h and the expression of CCR7 and CD45RA was analyzed in AIM⁺

480 (CD137⁺OX40⁺) CD4⁺ (a,c) and AIM⁺ (CD137⁺CD69⁺) CD8⁺ (b,d) T cells. a,b, Gating strategies

for identifying each memory subset among AIM⁺CD4⁺ (**a**) or AIM⁺CD8⁺ (**b**) T cells. **c,d,** Scatter

482 plots showing the relationship between DPSO and the proportion of the indicated subsets among AIM⁺CD4⁺ (**c**) or AIM⁺CD8⁺ 483 (**d**) T cells. **e,** PBMC samples (n=47) from individuals with 484 SARS-CoV-2 infection (n=34) were stimulated with OLPs of S, M, or N (1 μg/mL) for 24 h and 485 the frequency of T_{SCM} (CCR7⁺CD45RA⁺CD95⁺) cells was analyzed in AIM⁺CD4⁺ (upper) and 486 AIM⁺CD8⁺ (lower) T cells. Left, The gating strategy for identifying T_{SCM} cells. Right, Scatter 487 plots showing the relationship between DPSO and the proportion of T_{SCM} cells among 488 AIM⁺CD4⁺ or AIM⁺CD8⁺ T cells. The black line is a LOESS smooth nonparametric function, and 489 the grey shading represents the 95% confidence interval (**c,d,e**).

490

491 • Fig. 4. Frequency and differentiation status of SARS-CoV-2-specific MHC-I multimer⁺ T cells. 492 PBMC samples (n=15) from individuals with SARS-CoV-2 infection (n=11) were analyzed by 493 flow cytometry. **a,** Representative flow cytometry plots showing the *ex vivo* detection of 494 SARS-CoV-2 S₂₆₉ multimer⁺CD8⁺ T cells in the gate of CD3⁺ T cells. **b**, Scatter plot showing the 495 relationship between DPSO and the frequency of SARS-CoV-2 S₂₆₉ multimer⁺ cells among total CD8⁺ 496 T cells. Samples from the same patient are connected by solid lines. **c,d,** The 497 expression of CCR7, CD45RA, and CD95 was analyzed in SARS-CoV-2 S₂₆₉ multimer⁺CD8⁺ T 498 cells. IAV MP58 multimer⁺ (n=5) and CMV pp65495 multimer⁺ (n=6) cells from the PBMCs of 499 healthy donors were also analyzed. Representative flow cytometry plots (**c**) show the 500 proportion of the indicated subsets among multimer⁺ cells, and scatter plots (**d**) show the 501 relationship between DPSO and the proportion of the indicated subsets among SARS-CoV-2 502 S269 multimer⁺ cells. Samples from the same patient are connected by solid lines. Summary 503 data showing the proportion of the indicated subsets among IAV multimer⁺ and CMV multimer⁺ 504 cells are also presented (**d**). Horizontal lines represent median. **e,** A representative 505 flow cytometry plot (upper) and summary data (lower) showing the percentage of PD-506 1⁺TIGIT⁺ cells among SARS-CoV-2 S₂₆₉ multimer⁺ cells and total CD8⁺ T cells. Statistical 507 analysis was performed using the Wilcoxon signed-rank test (**e**). **P < 0.01. 508

509 **Fig. 5. Polyfunctionality and proliferation capacity of SARS-CoV-2-specific T cells. a-d,**

510 PBMC samples (n=90) from individuals with SARS-CoV-2 infection (n=39) were stimulated

511 with OLPs of S, M, or N (1 μg/mL) for 6 h. Intracellular cytokine staining was performed to

 512 examine the frequency of polyfunctional cells exhibiting positivity for ≥ 2 effector functions

513 among SARS-CoV-2-specific CD4⁺ and CD8⁺ T cells. **a**, Representative flow cytometry plots 514 showing the frequency of polyfunctional cells among CD4⁺ (left) and CD8⁺ (right) T cells. **b**, 515 Scatter plots showing the relationship between DPSO and the frequency of polyfunctional 516 cells among SARS-CoV-2-specific CD4⁺ (upper) or CD8⁺ (lower) T cells. The black line is a 517 LOESS smooth nonparametric function, and the grey shading represents the 95% confidence 518 interval. c, The fraction of polyfunctional cells among SARS-CoV-2-specific CD4⁺ (left) or CD8⁺ 519 (right) T cells was compared between T1 (n=17, 31 - 99 DPSO), T2 (n=39, 100 - 199 DPSO), 520 and T3 (n=25, 200 - 254 DPSO). Data are presented as median and IQR. **d,** Pie charts showing 521 the fraction of cells positive for a given number of functions among SARS-CoV-2-specific 522 CD4⁺ (left) or CD8⁺ (right) T cells. Each arc in the pie chart represents the indicated function. 523 **e,** CTV-labeled PBMCs (n=11) obtained after 200 DPSO were stimulated with S OLP pool (1 $524 \mu g/mL$ for 120 h and the frequency of CTV^{Iow} and Ki-67⁺ cells among CD4⁺ T cells was 525 analyzed. Representative plots (upper) and summary data (lower) are presented. Statistical 526 analysis was performed using the Kruskal-Wallis test with Dunns' multiple comparisons test 527 (**c**) or the Wilcoxon signed-rank test (**e**). n.s, not significant, ***P < 0.001.

Days post-symptom onset

Pie: # of functions
 $\begin{array}{|c|c|c|c|}\n\hline\n\bullet & 4 & \bullet & 3 & \bullet & 2\n\end{array}$

 \blacksquare 4 \blacksquare 3 \blacksquare 2 \blacksquare 1

Arc: type of function

CD107a⁺ ■ IFN-γ⁺ ■ IL-2⁺ ■ TNF+

ሰተ DMSO S

DMSO S

0^L 21

All rights reserved. No reuse allowed without permission.

Supplementary Table 1. Characteristics of enrolled patients

IQR, interquartile range; DPSO, days post-symptom onset; ELISpot, enzymelinked immunospot; ICS, intracellular cytokine staining; AIM, activationinduced marker; CTV, CellTrace Violet.

^aDisease severity was defined by the NIH severity of illness categories**.**

All rights reserved. No reuse allowed without permission.

Supplementary Table 2. Flow cytometry reagents

Extended Data Fig. 1. Proportion of S-, M-, and N-specific IFN-γ responses among total IFN-γ responses. PBMC samples from individuals with SARS-CoV-2 infection were stimulated with OLPs of S, M, or N (1 μg/mL) for 24 h and spot-forming units of IFN-γ-secreting cells were examined by ELISpot. Pie charts showing the proportion of S-, M-, and N-specific IFN-γ responses among the total IFN-γ responses in T1 (n=46, 31 - 99 DPSO), T2 (n=37, 100 - 199 DPSO), and T3 (n=23, 200 - 254 DPSO).

Extended Data Fig. 2. Correlation between the frequency of CD137+OX40+ cells and the frequencies of alternative AIM+ cells (OX40+CD154+ or CD137+CD154+ cells) among CD4+ T cells. PBMC samples from individuals with SARS-CoV-2 infection were stimulated with OLPs of S, M, or N (1 μg/mL) for 24 hours, and the correlation between the frequency of CD137+OX40+ cells and the frequencies of alternative AIM+ cells (OX40+CD154+ or CD137+CD154+ cells) among CD4⁺ T cells was analyzed (n=78). Statistical analysis was performed using the Spearman correlation test.

Extended Data Fig. 3. Correlation of the frequency of AIM+ cells between CD4+ and CD8+ T cells. PBMC samples from individuals with SARS-CoV-2 infection were stimulated with OLPs of S, M, or N (1 μg/mL) for 24 h and the correlation between the frequency of AIM+ (CD137+OX40+) cells among CD4+ T cells and AIM+ (CD137+CD69+) cells among CD8⁺ T cells was analyzed (n=125). Statistical analysis was performed using the Spearman correlation test.

Extended Data Fig. 4. Frequency of T_{SCM} cells among SARS-CoV-2-specific T cells according to days post-symptom **onset. a,b,** PBMC samples from individuals with SARS-CoV-2 infection were stimulated with OLPs of S, M, or N (1 μg/mL) for 24 h and the frequency of T_{SCM} (CCR7⁺CD45RA⁺CD95⁺) cells was analyzed among AIM⁺ (CD137⁺OX40⁺) CD4⁺ (a) and AIM⁺ (CD137⁺CD69⁺) CD8⁺ T cells (b). The frequencies of T_{SCM} cells were compared between T1 (n=12, 31 - 99 DPSO), T2 (n=14, 100 - 199 DPSO), and T3 (n=20, 200 - 254 DPSO). Data are presented as median and IQR. Statistical analysis was performed using the Kruskal-Wallis test with Dunns' multiple comparisons test. n.s, not significant.